CLINICAL TRIAL OF BRL 28500 (CLAVULANIC ACID-TICARCILLIN) IN THE TREATMENT OF CHRONIC SUPPURATIVE OTITIS MEDIA

• Published in: CHEMOTHERAPY Vol. 34; no. Supplement4; pp. 1120 - 1124
• Main Authors: TACHIBANA, MASAYOSHI, OHSHIMA, WATARU, MIZUKOSHI, OSAMU, YANOHARA, KUNIO, NISHIMURA, TAKESHIGE
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1986
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.34.Supplement4_1120

Clinical effect of BRL 28500, a 15:1 combination of Ticarcillin (TIPC) which is an anti-bacillus pyocyaneus semi-synthetic penicillin and Clavulanic acid (CVA) which is a β-lactamase inhibitor on chronic suppurative otitis media was studied. Patients were 3 males and 9 females whose ages ranged from 23 to 61 years old. Skin test with BRL 28500 were negative in all the patients. BRL 28500, in a dose of either 1.6g or 3.2g was administered once or twice a day via one shot i. v. injection or i. v. drip-infusion for 3 to 7 days. In 5 patients receiving a dose of 1.6g×2 times/day, the clinical results were good in 3, fair in 1 and poor in 1. All the isolated bacteria, each one strain of S. epidermidis, Staphylococcus sp., S. viridans, Neisseria sp., Alcaligenes sp. and Flavobacterium sp. were eradicated following the treatment with BRL 28500. In 7 patients receiving a dose of 3.2g/day, the clinical results were fair in 2 and poor in 5. The isolated bacteria consisting of 3 strains of S. aureus, 2 strains of P. aeruginosa, 1 strain of P. stuartii and 2 strains of Alcaligenes sp. were eradicated except for 2 strains of S. aureus, 1 strain of P. aeruginosa and 1 strain of Alcaligenes sp. One strain of P. aeruginosa not producing β-lactamase changed to P. aeruginosa producing β-lactamase. Synergetic action from viewpoint of MIC values due to the combination of CVA was seen only in coagulase-negative Staphylococcus sp. among the isolated bacteria. No side-effects were noted in any of the patients.